Pressrelease 10 July 2006
Patent Application Submitted for the GLX Compunds
The Lead candidate drug GLX010 belongs to a chemical group of small low molecular entities and has shown positive effects in insulin sensitising and lowering of blood glucose levels in diabetic animals. Next is to reveal the mode of action for the GLX compounds and to define how they are distinct from that of other compounds currently in clinical development.
Download a pdf of the Pressrelease
Pressrelease 15 May 2007
Promising Results in Treatment with GLX
Pressrelease 29 December 2006
US Patent Received for Diabetes Treatment
Pressrelease 28 September 2006
Glucox' Unique Research Discovery Confirmed by US Scientist
Pressrelease 10 July 2006
Patent Application Submitted for the GLX Compounds
Pressrelease 5 June 2006
A Significant Preclinical Milestone Achieved
Pressrelease 7 February 2006
Positive Results from the First Time In Animal Study
Pressrelease 10 January 2006
Pressrelease 10 November 2005
Evaluation and Selection of Glucox Biotech' Lead Drug Candidates